Fig. 1.
Fig. 1. Phenotype of blood DC before and after G-CSF treatment. / Peripheral blood samples were collected from the same donor before (left) and after (right) G-CSF treatment. After lysis of erythrocytes, cells were labeled with anti-HLA-DR PerCP, anti-IL-3Rα or anti-CD4 PE, anti-CD11c APC, and a mixture of FITC-conjugated mAbs specific for lineage markers CD3, CD14, CD16, CD19, CD20, CD34, CD56, and IgM expressed on lymphocytes, monocytes, granulocytes and progenitor cells (lineage FITC). Cells were then analyzed by 4-color flow cytometry. (A) Dendritic cells were characterized by positive HLA-DR and negative lineage markers. (B) Scatter profile of granulocytes (Gr), monocytes (Mo), and lymphocytes (Ly). (C) Scatter profile of DC, as gated in A. (D) DC were analyzed for the expression of IL-3Rα and CD11c or (E) CD4 and CD11c.

Phenotype of blood DC before and after G-CSF treatment.

Peripheral blood samples were collected from the same donor before (left) and after (right) G-CSF treatment. After lysis of erythrocytes, cells were labeled with anti-HLA-DR PerCP, anti-IL-3Rα or anti-CD4 PE, anti-CD11c APC, and a mixture of FITC-conjugated mAbs specific for lineage markers CD3, CD14, CD16, CD19, CD20, CD34, CD56, and IgM expressed on lymphocytes, monocytes, granulocytes and progenitor cells (lineage FITC). Cells were then analyzed by 4-color flow cytometry. (A) Dendritic cells were characterized by positive HLA-DR and negative lineage markers. (B) Scatter profile of granulocytes (Gr), monocytes (Mo), and lymphocytes (Ly). (C) Scatter profile of DC, as gated in A. (D) DC were analyzed for the expression of IL-3Rα and CD11c or (E) CD4 and CD11c.

Close Modal

or Create an Account

Close Modal
Close Modal